Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Non Operating Income: 2022-2025

Historic Other Non Operating Income for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to $3.1 million.

  • Kiniksa Pharmaceuticals International's Other Non Operating Income rose 27.64% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year increase of 10.02%. This contributed to the annual value of $9.5 million for FY2024, which is 10.77% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Other Non Operating Income of $3.1 million as of Q3 2025, which was up 15.42% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Other Non Operating Income peaked at $3.1 million during Q3 2025, and registered a low of $34,000 during Q1 2022.
  • Its 3-year average for Other Non Operating Income is $2.4 million, with a median of $2.4 million in 2023.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first spiked by 5,288.24% in 2023, then fell by 2.07% in 2024.
  • Kiniksa Pharmaceuticals International's Other Non Operating Income (Quarterly) stood at $794,000 in 2022, then skyrocketed by 198.36% to $2.4 million in 2023, then fell by 2.07% to $2.3 million in 2024, then grew by 27.64% to $3.1 million in 2025.
  • Its Other Non Operating Income was $3.1 million in Q3 2025, compared to $2.7 million in Q2 2025 and $2.3 million in Q1 2025.